Precigen, Inc. (PGEN) vs uniQure N.V. (QURE)

Precigen, Inc. and uniQure N.V. are both Biotechnology companies. Precigen, Inc. and uniQure N.V. are of similar size ($1.5B and $1.5B). uniQure N.V. has negative trailing earnings, so its P/E is not meaningful; Precigen, Inc. trades at 60.3×. Precigen, Inc. grew revenue faster over the last twelve months: 2,387.6% against 28.0%. Precigen, Inc. has the higher net margin (15.6% vs −1,154.8%) and the higher return on invested capital (15.9% vs 0.00%). Across the 18 metrics below, Precigen, Inc. leads on 12 and uniQure N.V. on 6.

Valuation

Metric PGEN QURE Biotechnology median
P/E 60.27 n/m 10.60
P/S 10.11 74.94 9.40
P/B 18.94 5.13 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 43.41 n/m 0.66
EV/Sales 10.51 44.70 9.02
Earnings yield 1.66% (16.22%) (32.88%)
Free cash flow yield (4.68%) (12.91%) (23.13%)

Profitability

Metric PGEN QURE Biotechnology median
Gross margin 91.42% 93.85% 68.51%
Operating margin 21.43% (1,001.74%) 0.00%
Net margin 15.55% (1,154.84%) 0.00%
Free cash flow margin (47.35%) (956.80%) 0.00%
Return on equity 38.84% (88.99%) (51.96%)
Return on assets 12.73% (25.47%) (46.06%)
Return on invested capital 15.93% 0.00% 0.00%

Growth

Metric PGEN QURE Biotechnology median
Revenue growth (TTM) 2,387.61% 28.04% 6.76%
EPS growth (last fiscal year) (191.49%) 29.67% 29.88%
Revenue growth, 5-year CAGR (21.26%) (15.57%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PGEN QURE Biotechnology median
Debt to equity 1.12 0.17 0.00
Current ratio 5.58 11.52 4.97
Net debt to EBITDA 0.04 3.36 1.01

Dividend

Metric PGEN QURE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PGEN QURE Biotechnology median
Market cap 1.51b 1.46b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack